Critics question FDA's endorsement of colchicine rival

01/18/2010 | Los Angeles Times (tiered subscription model)

Several rheumatologists and patient advocates are criticizing the FDA for granting market exclusivity to a rival of colchicine, an unapproved but widely used treatment for gout and familial Mediterranean fever. While the agency cited safety concerns as a reason for endorsing URL Pharma's Colcrys, opponents argued that the brand-name drug is no better or safer than the cheaper formulations and is much more expensive.

View Full Article in:

Los Angeles Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY